Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies.
He
Yuxian
Y
New York Blood Center, New York, New York 10021, USA.
D000914:Antibodies, Viral; D018604:Epitope Mapping; D000939:Epitopes / Q000737:chemistry; D008562:Membrane Glycoproteins / Q000737:chemistry* / Q000502:physiology*; D009500:Neutralization Tests; D011485:Protein Binding; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D045473:Severe acute respiratory syndrome-related coronavirus / Q000378:metabolism*; D045169:Severe Acute Respiratory Syndrome / Q000821:virology*; D064370:Spike Glycoprotein, Coronavirus; D014759:Viral Envelope Proteins / Q000737:chemistry* / Q000502:physiology*; D014765:Viral Vaccines / Q000737:chemistry
D000914:Antibodies, Viral; D000939:Epitopes; D008562:Membrane Glycoproteins; D064370:Spike Glycoprotein, Coronavirus; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C578557:spike glycoprotein, SARS-CoV; C578553:spike protein, mouse hepatitis virus